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ABSTRACT
JAMES RICARD MICHELS: Th1, Th2 and Th 17 inflammatory pathways predict
cardiometabolic protein expression in serum of COVID-19 patients.
(Under the direction of Ana Pavel)

A predominant source of complications in SARS-CoV-2 patients arises from severe
systemic inflammation contributed to by Helper T-cell associated cytokines, potentially leading to
tissue damage and organ failure. The high inflammatory burden of this viral infection often results
in cardiovascular comorbidities. A better understanding of the interaction between the cytokine
storm and cardiovascular proteins might inform medical decisions and therapeutic approaches. We
hypothesized that all major helper T-cell inflammatory pathways (Helper T 1, Helper T 2 and
Helper T 17) synergistically contribute to cardiometabolic pathways in serum of COVID-19
patients, and that both of these factors correlate to COVID-19 severity. We found that Helper T 1,
Helper T 2, and Helper T 17 cytokines and chemokines are able to predict expression of 186
cardiometabolic proteins profiled by OLINK proteomics.
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CHAPTER 1
INTRODUCTION
COVID-19 disease, since its discovery in 2019, has caused a large amount of damage
throughout the world, resulting in massive strain on hospital systems, and, sadly, many patient
deaths (Satiani et al., 2020). A major point of study is through patient proteomic profiles, which
consists of chemical signals such as cytokines and chemokines (Stenken et al., 2016). Patient
proteomic profiles, in conjunction with computational analysis through correlation methods can
be used to gain a greater understanding of the interactions of these chemical signals in
inflammatory diseases. This could allow for the enhanced development of therapies to prevent the
cardiovascular complications such as myocardial strain and hypertension associated with
associated proteins or the cytokines (Del Valle et al., 2020).
This study explores how the presence of cardiometabolic proteins and helper T cell
associated cytokines and chemokines from day zero data affect patient outcomes. The dataset that
is being used in this analysis originates from the Massachusetts General Hospital COVID-19
Registry, and the study takes a large number of patient proteomic profiles being analyzed through
computational modelling in order to correlate the presence of markers and proteins with patient
severities versus a control group (Pavel et al., 2021). After this, the cytokines and chemokines are
modelled in relation to cardiometabolic proteins in order to create a set of networks that will map
the large number of signals that take part in the activation or suppression of these cardiometabolic
proteins.
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CHAPTER 2
BACKGROUND
2.1

COVID-19

2.1.1

COVID-19 BACKGROUND
The respiratory virus SARS-CoV-2 has caused over 200 million reported cases of COVID-

19 Disease and over 5 million reported deceased to date (Dong et al., 2020). Strides have been
made in the treatment of this virus through the development of the vaccinations to prevent infection
and specialized treatments such as the monoclonal antibody infusions (Brobst et al., 2022). Despite
this, more research into the treatment of COVID-19 is needed, as there are many dangerous
complications such as acute respiratory distress syndrome, respiratory failure, hepatic and renal
insufficiency in severe cases (Yang et al., 2021). Cardiovascular complications such as
hypertension and myocardial injury have also been shown in severe COVID-19 cases, and are the
main interest of this study (Guo Tao et al., 2020). Proteomic profiling is a method that can study
the cytokines and chemokines in the cardiometabolic system to potentially open doors for the
development of immunomodulatory therapies in the future (Yu et al., 2021).
2.1.2 ROLE OF CYTOKINES AND CHEMOKINES IN COVID-19
Cytokines and chemokines, often referred together as markers, are signal molecules
released by Helper T cells in an immune response (Dong, C et al., 2021). Each type of Helper T
immune cell reacts to a different potential threat to the body. The three Helper T cells that are the
focus of this study are selected for their implications in the body’s reaction to COVID-19. Helper
2

T 1 cells react to viruses (Alberts et al., 2002), Helper T 2 cells react to antigens such as the
COVID-19 spike protein (Wu et al., 2021), and Helper T 17 cells play a role in adaptive immunity
(Khader et al., 2009), often acting in coordination with the Helper T cells during an autoimmune
response.
Recent research has shown that a shift in the balance of Helper T 1 and Helper T 2
associated markers, with an increase in Helper T 2 expression, is correlated with an increase in
severity in COVID-19 (Pavel et al., 2021). Research on atopic patients also has shown that patients
treated with Helper T 2 inhibitors have displayed more asymptomatic cases (Ungar et al., 2022).
The study of cytokines and chemokines is fundamental towards understanding the body’s
reaction to viral infection by COVID-19 because these signals play a key role in the reaction and
possible overreaction in the immune system. In this process referred to as cytokine storm, there is
an elevated expression of inflammatory helper-T-cell-associated cytokines (Fajgenbaum et al.,
2020). Many effects of the COVID-19 disease are believed to be as a result of cytokine storm, and
this can lead to complications. Expressed proteins that have been associated with negative sideeffects are expressed more, and this can worsen a patient’s condition. In the DISCUSSION section,
more is discussed on proteins’ effects on patients. However, cytokine storm is not necessary for
complications to occur. Figure 2.1 shows an infographic on cytokine storm.
Cytokines and chemokines are deeply involved in the body’s processes involved in the
reaction to COVID-19 through response pathways. Response pathways describe the roles
cytokines play in the complex interactions of viral infection. These pathways can be incredibly
detailed, with databases such as the regularly updated KEGG PATHWAY Database (Kanehisa et
al., 2000) displaying the many cytokines and chemokines involved in the process of COVID-19
infection, such as the example in Figure 2.2.
3

Figure 2.1: Cytokine Storm Infographic (Modified from Al-Kuraishy et al. 2020)

4

Figure 2.2 COVID Pathway from KEGG Database (Kanehisa et al., 2000)
5

2.2

PROFILING METHOD
The cytokines and proteins to be studied were profiled by the OLINK Explore 1536

Proteomics Assay. The OLINK Explore 1536 Proteomics Assay originally released in the summer
of 2020, and is used for the screening of protein biomarkers (Olink 2021). The assay measures
over 1500 proteins in 88 samples with less than 3 microliters of sample each (Olink 2021). The
platform uses a semi-automated process where robots perform the entire assay except for plate
transfer and sealing (Olink 2021). The automation makes the experiment repeatable and
reproducible. The four panels of focus are inflammation, oncology, neurology, and
cardiometabolic proteins (Olink 2021). Of these four panels, cardiometabolic proteins are of
interest in the study, as no prior study has used integrated major Helper T pathways to evaluate the
implications of COVID-19 cytokine expression on cardiometabolic proteins.
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CHAPTER 3
DATASET
3.1

DATASET ORIGIN
The dataset originates from a Massachusetts General Hospital system study, with the data

on 383 patients being collected on September 2020. The first study analyzed this dataset in order
to generate a model of immune and epithelial cell interactions that are involved in cell-specific or
tissue-specific damage in cases of COVID-19 (Filbin et al., 2020). The research described in this
thesis is intended to analyze the cardiometabolic interactions that shape the body’s response to
COVID-19.
3.2

PARAMETERS
The data was obtained in two datasets, a clinical info dataset and a blood marker dataset.

The recorded parameters in the clinical info dataset included the following:


Subject ID of the Patient



COVID status of the Patient



Age Group of the Patient



BMI Group of the Patient



Presence of other conditions such as diabetes or kidney disease



Presence of certain symptoms



Disease severity
7

The severity was checked at 0, 3, 7, and 28 days after admission into the hospital system.
The blood marker dataset contained the results of the OLINK Explore 1536 Proteomics
assays, which contained the limit of detection, the threshold for a valid reading from the assay,
and normalized protein expression, the expressed level of a tested protein, for the presence of
cardiometabolic proteins and Helper T-associated markers. The main focus of the research
project described in this thesis was on the day zero data, COVID-19 status, and normalized
protein expression readings.
3.3

PRELIMINARY CHANGES TO THE DATASET
The data was modified in a myriad of ways to make the managing of the data less

complicated. One modification was the removal of one patient, patient number 365, for missing a
normalized protein expression value for the Interferon Gamma 1 marker, IFNGR1. Every other
patient displayed readable normalized protein expression levels for every other cardiometabolic
protein of interest.
Another modification was changing the outcome severity scale from a five-point scale, as
displayed in Figure 3.1, to a three-point scale. The intent of this change was to simplify the fivepoint scale, with level 3 (hospitalized with supplemental oxygen), 4 (hospitalized without
supplemental oxygen), and 5 (discharged from emergency department), being merged into one
“non-severe” outcome group as these levels, albeit admitted to the hospital, were not severe
enough to warrant intubation. This was to simplify the patient groups so that the heatmaps could
be simplified and that three groups could be focused on in the research: Deceased, Intubated, and
Non-severe.
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In the code that processed the data, the data was also processed at points to separate the
COVID-19 Positive and COVID-19 Negative patients, so that the proteomic data of the
individual groups could be processed. This would allow the COVID-19 Negative patients to act
as a control group, with the COVID-19 Positive patients to act as the experimental group.

Figure 3.1: Original Five Point Scale from the Massachusetts General Hospital Study
(Filbin et al. 2020)
3.4

STATISTICS ON EXPERIMENTAL AND CONTROL GROUPS
The patients were separated into COVID-19 Positive and COVID-19 Negative groups,

with 306 and 78 patients respectively. The original study from which the dataset originated found
that the COVID-19 Positive patients displayed a younger median age as compared to the COVID19 Negative patients, with median ages for each group of 58 and 67 years, respectively (Filbin et
al., 2020). The COVID-19 Positive patients in this study were also found to be mostly Hispanic,
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with 54% of the COVID-19 Positive group being Hispanic as compared to 15% of the COVID-19
Negative group (Filbin et al., 2020).
The patients of the study, as classified by severity, were grouped into 49 deceased patients,
83 intubated patients, and 251 non-severe patients. Of the 49 deceased patients, 42 were COVID19 Positive and 7 were COVID-19 Negative. Of the 83 intubated patients, 67 were COVID-19
Positive and 16 were COVID-19 Negative. Of the 251 non-severe patients, 196 were COVID-19
Positive, and 55 were COVID-19 Negative.
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CHAPTER 4
METHODOLOGY
4.1

CYTOKINE/CHEMOKINE SELECTION AND VARIABLES
The Helper T 1, Helper T 2, and Helper T 17 cytokines and chemokines were classified

based on previous study in various inflammatory diseases for their characterized pathways and
response to different targeted biologics (Pavel et al., 2021). The following cytokines and
chemokines were detectable by the OLINK Explore Proteomics Assay:


11 Helper T 1 markers: CCL3, CCL6, CXCL11, CXCL10, CXCL9, IL2RA, IFNG,
IFNGR1, IFNGR2, IL12B, and IL1B



14 Helper T 2 markers: CCL11, CCL13, CCL17, CCL22, CCL24, CCL26, CCL7, IL10,
IL13, IL33, IL4R, IL5, IL7R, and TSLP



13 Helper T 17 markers: CCL20, S100P, IL6, IL6R, LCN2, S100A12, CXCL1, PI3,
IL17A, IL17F, CXCL3, IL12A, and IL12B

These cytokines and chemokines were used in the study as the markers to be correlated with
cardiometabolic proteins expression and patient outcomes for both the COVID-19 Positive and
COVID-19 Negative groups. There are three main correlations of focus studied in this research,
each with their own independent and dependent variables: The correlation between
cardiometabolic protein expression (dependent variable) and cytokines/chemokine expression
(independent variables), the correlation between cytokine/chemokine expression (dependent
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variable) and disease severity (independent variable), and the correlation between cardiometabolic
protein expression (dependent variable) and disease severity (independent variable).
4.2

R PACKAGES USED
All statistical analyses for this study were performed using the R programming language.

A functionality of R that was instrumental to the data processing was the use of external R
packages. Packages are extensions of R that contain specific functions and data sets suited towards
different needs, and can be downloaded from within the R program. After packages are
downloaded onto the RStudio client, they can be called from a directory called “library”, which
allows them be called for use. Further discussed below are the R packages used, and the role which
each package played within the generation of the results.
4.2.1 GLMNET – LINEAR MODELLING
The glmnet R package is a package designed for lasso and other generalized linear models
to perform linear regression (r-project 2021). The glmnet R package was used to perform the
generalized linear models that were required for the correlations. The package’s cv.glmnet
function was used to predict the expression levels of each cardiometabolic protein based on Helper
T 1, Helper T 2, and Helper T 17 cell immune profiles using 10-fold cross-validation. The model
can be summarized by using the following equation:

𝑦

is a continuous variable representing the predicted expression of each

cardiometabolic protein modelled by a weighted sum across the Helper T 1, Helper T 2, and Helper
12

T 17 cytokines and chemokines. The weights of the model, represented by 𝑎 , 𝑏 , and 𝑐 , are
estimated by the elastic net regularized linear regression. The best fit of linear predictions was
calculated by Pearson correlation between the predicted and measured expression of each
cardiometabolic protein. These predictions were then ranked among all 355 cardiometabolic
proteins and were considered as a significant best fit if those predictions had an r value greater
than or equal to 0.7, and an adjusted p-value less than 0.05.
4.2.2 IGRAPH – NETWORK GENERATION
The igraph R package contains network analysis tools that are used in order to efficiently
generate network graphs, which allow connections or correlations in data to be visually displayed
(igraph 2020). The igraph R package was used to visualize the interaction between immune and
cardiometabolic markers with a Pearson correlation r value greater than or equal to 0.7. The edges
of the networks generated represent non-zero coefficients of the elastic net regression model with
an absolute value greater than or equal to 0.05. This choice was to filter noise and very weak
interactions. These generated networks were additionally color-coded by changing the color of
certain vertices.

Figure 4.1: Planned Network Cytokine and Chemokine Legend
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The color scheme, as displayed in Figure 4.1, allows for both positive and negative links
between cytokine or chemokine and cardiometabolic protein to be identifiable, as well as clearly
differentiating which Helper T cell the cytokine or chemokine is associated with.
4.2.3 GGPLOT2 – BAR GRAPH GENERATION
The ggplot2 R package is used for creating graphics, with a high degree of customizability
available to the user (tidyverse). It was used in this study to generate supplementary Pearson
scatterplots and in addition to a bar graph displaying the number of both positive and negative
links associated with the three studied types of Helper T cells and cardiometabolic proteins.
4.2.4 DPLYR – GRAMMAR AND CONSISTENCY
The dplyr R package is used for data manipulation, and adds a consistent set of verbs to
allow users to manipulate data in R more effectively. This was mainly a quality-of-life package
used in the study, but was still important in isolating certain parameters of the markers, such as the
subject ID, assay type, and normalized protein expression.
4.3

LASSO REGRESSION
Lasso regression, or Least Absolute Shrinkage and Selection Operator regression, is a type

of linear regression that is characterized by the use of shrinkage, where data values are shrunk
towards a central point, often a mean (Great Learning 2021). This method encourages models that
are less complex and have fewer parameters (Great Learning 2021). Lasso regression was used in
the generation of the correlations between cytokine expression and cardiometabolic protein
expression modelled in the heatmaps and networks.
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4.4

SUPPLEMENTAL DATA GENERATION
Supplemental data tables were generated to contain the raw values of the results of the

main analysis, in the form of the mean expression of each cytokine/chemokine and
cardiometabolic protein for each of the three patient groups and the logFCH, FCH, and p-values
for all comparisons between the groups. This was performed for both the COVID-19 Positive
group and the COVID-19 Negative group, as to show the data that is mainly implicated in the
generation of heatmaps and network plots.
The logFCH and FCH values are numerical means of measuring how much a quantity
changes between two measurements, which are the two compared patient groups
(RDocumentation 2021). The FCH value is alternatively recorded in a logarithmic format with a
base of two. The p-value is a statistic that refers to the likelihood of the data occurring under a null
hypothesis, which is a hypothesis stating that there is no difference between the tested groups
(Tanha et al., 2017). A significantly small p-value, a p-value less than 0.05, is considered ideal in
confirming the differences between any of the major three comparisons: Deceased versus Nonsevere, Intubated versus Non-severe, and Deceased versus Intubated.
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CHAPTER 5
RESULTS
5.1

HEATMAPS

5.1.1 CYTOKINE AND CHEMOKINE HEATMAPS
The cytokines and chemokines of the studied Helper T cell types were analyzed via
heatmaps in both COVID-19 Positive and COVID-19 Negative patients, shown in Figures 5.2 and
5.1, respectively. The heatmaps feature a color scale to display results, where a deeper red color
correlates to increased cytokine or chemokine expression, and a deeper blue color correlates to a
decreased cytokine or chemokine expression. The score is normalized to a z-scale, which is a color
scale from -1.5 to 1.5 standard deviations from the mean, with a negative standard deviation
meaning a standard deviation towards under-expression. This z-scale is displayed in Figure 5.3.
In most of the Helper T 1 and Helper T 17 markers, an increasing trend in protein
expression and COVID-19 severity was shown. This increasing trend has been displayed in over
half of the Helper T 2 markers as well. Significant increases, as denoted by a p-value < 0.05, were
found in a myriad of markers in deceased patients as compared to non-severe patients. These
significant markers are IFNGR1, CCL3, CCL4, CCL5, CXCL9, CXCL10, IL1B, and IL2RA for
Helper T 1 markers, CCL11, CCL13, CCL7, CCL24, and IL4R for Helper T 2 markers, and
S100A12, S100P, CCL20, LCN2, PI3, CXCL1, IL17A, and IL6 for Helper T 17 markers. COVID-
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19 Negative patients did not display any significant increasing trends in deceased patients as
compared to non-severe patients in the Helper T 1, Helper T 2, and Helper T 17 pathways.

Figure 5.1: COVID-19 Group Marker Heatmaps

Figure 5.2: Control Group Marker Heatmaps

Figure 5.3: Heatmap Color Key
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5.1.2 CARDIOMETABOLIC PROTEIN HEATMAP

Figure 5.4: Significant Cardiometabolic Protein Heatmaps
18

Of the 355 cardiometabolic proteins detected by the OLINK Explore Proteomics
assay, 35 cardiometabolic proteins were significantly associated with COVID-19 severity in
COVID-19 Positive patients, as judged by a fold change value greater than or equal to 2, and an
FDF value less than 0.05 in any of the three comparisons: deceased versus non-severe, intubated
versus non-severe, or deceased versus intubated.
A heatmap, shown in Figure 5.4, was generated to display the estimated mean expression
of the significant 35 cardiometabolic proteins stratified by COVID-19 severity. Notably, all 35 of
the significantly expressed proteins were significantly increased in deceased versus non-severe
COVID-19 Positive patient groups. Of the cardiometabolic proteins, LTBP2, RNASE3, CHI3L1,
CSTB, RETN, GDF15, CXCL8, PLA2G2A, IL1RL1, and NADK all showed significantly
elevated expression in intubated COVID-19 Positive patient groups versus non-severe patient
groups.
Additionally, a heatmap was generated for the 8 cardiometabolic proteins that were
significantly associated with severity in the COVID-19 Negative group, as defined by the same
criteria as the COVID-19 Positive significant cardiometabolic proteins. Notably, none of the 8
proteins have yielded significance when comparing the deceased versus non-severe patient groups,
and all of the 8 significant cardiometabolic proteins only displayed significance when comparing
the intubated versus non-severe COVID-19 Negative patient groups.
5.2

NETWORKS
Network graphs were generated of the 186 expressed cardiometabolic proteins to display

the interactions between the Helper T cytokines/chemokines and the cardiometabolic proteins.
Figure 5.5 displays examples of some of these network graphs. The network graphs appear as

19

many small colored vertices, representing the Helper T cytokines and chemokines, connected to a
large white vertex, representing a cardiometabolic protein. The vertices are all labelled as to
identify the markers protein, and the colors on the cytokines or chemokines correlate to which
Helper T cell that is associated with the cytokine or chemokine.

Figure 5.5: Example Significant Networks
20

Interestingly, a majority of links involved in these network plots are positive connections,
which means that the presence or expression of that cytokine or chemokine encourages the
expression of the cardiometabolic protein. This suggests that increased production in cytokines
and chemokines may stimulate the overall production of cardiometabolic proteins in response to
COVID-19 infection, which may correlate to increased side-effects associated with these proteins.

Figure 5.6: Overall Cardiometabolic Activation Network.
21

Figure 5.7: Overall Cardiometabolic Network Bar Graph
Another network graph, shown in Figure 5.6, generated was to display all positive
associations in a way to display the positive connections between cytokines or chemokines and
cardiometabolic proteins. The size of the colored vertices, which represent cytokines or
chemokines, correlate to the number of cardiometabolic proteins that the cytokine or chemokine
is positively linked to. A bar graph, shown in Figure 5.7, was created to enumerate the number of
positive, or activating, and negative, or suppressing, links between the cytokines or chemokines
and cardiometabolic proteins of interest. 367 positive links and 122 negative links are associated
with Helper T 1 cytokines or chemokines. 452 positive links and 90 negative links are associated
with Helper T 2 cytokines or chemokines. 546 positive links and 91 negative links are associated
with Helper T 17 cytokines or chemokines. The bar graph confirms that there are far more positive
links and interactions, which supports the previous suggestion.
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5.3

SUPPLEMENTARY DATA

5.3.1 PEARSON CORRELATION PLOTS

Figure 5.8: Pearson Scatter Plots
As part of supplementary data, scatter plots of the cardiometabolic protein Pearson
correlations were generated, which show how strong the correlation is between the predicted
cardiometabolic protein expression and the actual cardiometabolic protein expression. These
scatter plots, shown in Figure 5.8, were generated for every cardiometabolic protein investigated
in the study. In Figure 5.8, there are the scatter plots of twenty of the twenty-three significant

23

cardiometabolic proteins correlated with severity. All of these scatter plots feature positive
correlation, showing that the expression is expected and this helps confirm that the data is precise.
The Pearson correlation coefficient, r, measures how well a prediction model fits, with all r values
in the figure being greater than 0.7. The corresponding p-value is included for each protein as well.
5.3.2 MEANS, logFCH, FCH, AND p-value TABLES
After the generation of visualized data forms such as heatmaps and networks, the rest of
the data was put into tables, shown in Figure 5.9, 5.10, and 5.11, each concerning the Helper T
associated cytokines or chemokines. The statistics displayed through these tables identify the mean
expression of each cytokine or chemokine for each of the three patient groups and the logFCH,
FCH, and p-values for all comparisons between the groups.

Figure 5.9: Helper T 1 Marker Supplemental Data
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Figure 5.10: Helper T 2 Marker Supplemental Data

Figure 5.11: Th17 Supplemental Marker Data
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From this data, the process behind the generation of the heatmaps can be seen, as this data
is used during the generation of the heatmaps. The p-values are valuable as well, as they show that
some comparisons may not be as significant. A statistically significant comparison is represented
by a p-value less than 0.05. From this it can be seen that while some comparisons are not
statistically significant, but a large number are.
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CHAPTER 6
DISCUSSION AND FUTURE WORK
6.1

SIGNIFICANT CARDIOMETABOLIC PROTEINS IN DISEASE
Of the thirty-one cardiometabolic proteins that were noted for significant correlation with

COVID-19 severities, twenty-three have been highlighted as examples of cardiometabolic proteins
associated with involvement in cardiovascular-related diseases or, in the case of the
cardiometabolic protein GPR37, cardiovascular development.
LTBP2 has been identified previously as a marker associated with human heart failure (Bai
et al., 2012). CHI3L1 levels has been correlated with severity levels in coronary (Ściborski et al.,
2020) and carotid atherosclerotic plaque (Michelsen et al., 2010) as well as stroke (Ridker et al.,
2014). Elevated GDF15 levels have been associated with higher risks in multiple cardiovascular
diseases such as stable coronary artery disease, acute coronary syndrome, and heart failure (Kempf
et al., 2009). Elevated CXCL8 levels have been found, in previous research, in cases of
atherosclerotic plaque (Rus et al, 1996). SPP1 expression has been found to be higher in response
to ischemia associated with stroke (Zhu et al, 2017), myocardial infarction (Muller et al., 2011)
and peripheral artery disease (Koshikawa et al., 2009). FABP4 has been found to contribute to the
development of atherosclerosis, and studies shown that lower levels of FABP4 protect against
atherosclerosis to a degree (Makowski et al., 2001).
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REG1A has been shown to have high levels of expression in heart tissue of patients who
died of myocardial infarction (Kiji et al., 2005). TFF3 levels in sera have been linked to the
prediction of major adverse cardiovascular events in (Obendorf et al., 2015) as well as being
identified as a possible biomarker for myocardial infarction (Fernández et al., 2020). Il19 has been
found to have an athero-protective effect, with higher expression levels resulting in lower
atherosclerotic plaque lesion area in mice (Ellison et al., 2014). TNC has been previously linked
to many cardiovascular diseases in humans such as pulmonary thromboembolism (Celik et al.,
2011) and hypertension (Schumann et al., 2010). IL1RL1 has been studied as a meaningful marker
in cardiac disease, and found to have increased expression in the lungs in cases of heart failure
(Domingo et al., 2018). IL1RL1, a protein associated with general inflammation and
atherosclerosis, has also been shown to have significant upregulation in cases of both lesional and
non-lesional Atopic Dermatitis compared to controls. (Pavel et al., 2019). CSTB has been
identified as a relevant biomarker associated with chronic heart failure patients (Bouwens et al.,
2019).
NTproBNP has been shown to be a reliable biomarker in diagnostic evaluation and
outcome prediction in cases of acute heart failure, especially in dyspneic patients (Panagopoulou
et al., 2013; Januzzi et al., 2006). One study suggested that NTproBNP been seen as “as S.O.S.
signal” in heart failure, valvular heart diseases, pulmonary hypertension, and ACS. (Kimmenade
et al., 2007). Higher IGFBP1 expression has been previously related to lessened cardiovascular
risk factors and decreased presence of atherosclerosis in elderly patients (Janssen et al., 1998).
RETN has been implicated as a risk factor for cardiovascular diseases in patients with type 2
diabetes (Menzaghi et al., 2013).
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RNASE3 studies shown that depletion of RNASE3 lead to development of heart
disfunctions and induced apoptosis (Yamaguchi et al., 2004). DCN has been shown to play a
protective role against cardiac diseases such as atherosclerosis and myocardial infarction, where
DCN was found to reduce atherosclerosis development when overexpressed (Al Haj Zen et al.,
2006) and DCN was found to aid in proper fibrotic evolution in myocardial infarction (Weis et al.,
2005). Research has not yielded significant findings concerning the relations of GPR37 to
cardiovascular disease, but GPR37 does play a role in cardiovascular development, with a study
on mice finding GPR37 and GPR37L1 contributing to sexual dimorphism of central cardiovascular
control, controlling blood pressure in females and assisting cardiovascular response in males
(Coleman et al., 2018).
IGFBP2 expression was investigated in a study on pulmonary artery hypertension, and it
found that elevated IGFBP2 expression was associated with increased severity and mortality in
pulmonary artery hypertension cases (Yang et al., 2020). ACTA2 has been implicated in
cardiovascular disease, with a case study reporting how a mutation of ACTA2 led to pulmonary
hypertension and persistent ductus arteriosus, implicating ACTA2 in a role of cardiovascular
development (Meuwissen et al., 2013). Another study on ACTA2 mutations found that ACTA2
mutations can potentially lead to coronary artery disease, stroke, and Moyamoya disease (Guo et
al., 2009). PLA2G2A elevated expression has been associated with calcific aortic valve stenosis
in humans in previous research (Perrot et al., 2020).
Two other notable proteins, NAD Kinase (NADK) and Myoglobin (MB), are also notable
for the significant functions they perform within the body, even if they are not correlated in some
way with cardiovascular disease. NADK plays a role in cellular energy as it helps convert the
cellular energy carrier nicotinamide adenine dinucleotide (NAD) into its phosphorylated version
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NADP. MB plays a role in oxygen transport to the mitochondria of muscle cells through the use
of an iron molecule near the center of the protein’s structure. Both of these proteins are very
essential to the body’s functions and so the implications of NADK overexpression being correlated
to intubation and MB overexpression being correlated to deceased cases can be an interesting point
for future study.
In Figure 5.5, the networks of the twenty previously discussed proteins visualize what
cytokines influence their expression. Notably, the most common Th1 cytokine influence by far is
IFNGR1 present in seventeen of the twenty networks. The most common Th2 cytokine influences
are CCL11 and CCL7, each being present in ten and eight, respectively, of the twenty networks.
The most common Th17 cytokine influences include PI3 and LCN2, which both were present in
ten of the twenty networks, in addition to IL6 which was present in eight of the twenty networks.
The common cytokines or chemokines are significant as this information could illuminate what
the key players are in the Helper T response with reference to cardiometabolic proteins.
6.2

FUTURE STUDY
After the recent publication of the researched described in this thesis (Michels et al, 2021),

there are many paths that can be taken for future study. The same processing methods can be used
on other datasets of COVID-19 Patients that have undergone the same OLINK proteomics assay.
This would allow the results to be validated further or to see if there is a regional factor towards
the body’s cytokine and chemokine content, as the original study data acknowledges that the
research was performed on a large, urban population. While the groups are large enough for the
results to be considered statistically significant, larger groups of study would provide more data of
interest.
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Another further point of study is to use this process on the more recent variants of COVID19, such as the Omicron and Delta variants, which have been rising in more recent outbreaks.
These variants are characterized by higher transmissibility and lower lethality, which would
postulate an interesting question as to if the results would differ from the original variant. The
study of other variants would yield more information on how Helper T Cell cytokines and
chemokines interact the cardiometabolic proteins and outcomes.
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